{"resourceType": "Group", "meta": {"versionId": "16", "lastUpdated": "2024-08-01T12:27:35.568Z", "profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"]}, "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Sheyu Li"}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact", "valueRelatedArtifact": {"type": "cite-as", "citation": "Eligibility criteria for NMA_Diabetes [Database Entry: FHIR Group Resource]. Contributors: Sheyu Li [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 264323. Revised 2024-07-30. Available at: https://fevir.net/resources/Group/264323. Computable resource at: https://fevir.net/resources/Group/264323."}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-title", "valueString": "Eligibility criteria for NMA_Diabetes"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-url", "valueUri": "https://fevir.net/resources/Group/264323"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-publisher", "valueString": "Computable Publishing LLC"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-copyright", "valueMarkdown": "https://creativecommons.org/licenses/by-nc-sa/4.0/"}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-contact", "valueContactDetail": {"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/combination-method", "valueCode": "all-of"}], "id": "264323", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "https://fevir.net", "value": "264323", "assigner": {"display": "Computable Publishing LLC"}}], "characteristic": [{"code": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/181513", "code": "SEVCO:01000", "display": "Study Design"}], "text": "Study design"}, "valueCodeableConcept": {"coding": [{"system": "http://hl7.org/fhir/study-design", "code": "SEVCO:01003", "display": "randomized assignment"}]}, "exclude": false, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "The study design is a randomised controlled trial."}]}, {"code": {"text": "Study population"}, "valueReference": {"reference": "Group/265093", "type": "Group", "display": "Adults with type 2 diabetes"}, "exclude": false, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "All the participants are adults with type 2 diabetes."}]}, {"code": {"text": "Study interventions"}, "valueReference": {"reference": "Group/265092", "type": "Group", "display": "Diabetes treatment medication"}, "exclude": false, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "The medication class should be among one or more of SGLT-2 inhibitors, GLP-1 receptr agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, sulfonylureas, metformin, \u03b1-glucosidase inhibitors, meglitinides, insulins, dual GIP/GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists."}]}, {"code": {"text": "Duration of follow up"}, "valueQuantity": {"comparator": ">=", "value": 24, "unit": "weeks", "system": "http://unitsofmeasure.org", "code": "wk"}, "exclude": false, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "Eligible trials had a follow-up of 24 weeks or longer."}]}, {"code": {"text": "Language of publication"}, "valueCodeableConcept": {"coding": [{"system": "urn:ietf:bcp:47", "code": "en", "display": "English"}]}, "exclude": false, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "We excluded non-English language published studies."}]}, {"code": {"text": "Defined by CodeableConcept"}, "valueCodeableConcept": {"text": "Systematically comparing combinations of more than one drug treatment class with no drug treatment"}, "exclude": true, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "We excluded trials systematically comparing combinations of more than one drug treatment class with no drug treatment."}]}, {"code": {"text": "Defined by CodeableConcept"}, "valueCodeableConcept": {"text": "Subgroup analyses"}, "exclude": true, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/characteristic-description", "valueMarkdown": "We excluded subgroup analyses of randomised controlled trials."}]}], "description": "Eligible randomised controlled trials compared drugs used to treat adults with type 2 diabetes. We considered the following drug classes: SGLT-2 inhibitors, GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, sulfonylureas, metformin, \u03b1-glucosidase inhibitors, meglitinides, insulins, dual GIP/GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists. Appendix 1.3 describes the detailed drug names and definitions of control arms (typically standard treatment at the time the trials were conducted, representing the treatment regimens the patient received before the clinician considered adding a new drug). Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug treatment, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible.", "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>"}, "membership": "definitional", "code": {"text": "Research study"}, "modifierExtension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-status", "valueCode": "active"}], "type": "animal"}